JBJS Open Access (Jun 2017)

Partial Resurfacing of the Knee with the BioPoly Implant

  • Dinesh Nathwani, MB, ChB, MSc, FRCS(Tr&Orth),
  • Michael McNicholas, BSc, MB, ChB, FCRS(Ed&Glasg), MD, FRCSEd(Tr&Orth), FFSEM RCSI,
  • Alister Hart, MA, MD, FRCSG(Orth),
  • Jonathan Miles, MD, FCRS(Orth),
  • Vladimir Bobić, MD, FRCSEd

DOI
https://doi.org/10.2106/JBJS.OA.16.00011
Journal volume & issue
Vol. 2, no. 2
p. e0011

Abstract

Read online

Background:. Current treatments for focal chondral and osteochondral lesions of the femoral condyle have been associated with variable outcomes. We conducted a clinical trial of the BioPoly RS Partial Resurfacing Knee Implant to address this unmet need. Methods:. We performed a single-arm, prospective study in which 33 patients with focal cartilage lesions affecting the femoral condyle were managed with the BioPoly RS Partial Resurfacing Knee Implant. Knee injury and Osteoarthritis Outcome Score (KOOS) scores, a visual analog scale (VAS) for pain, the Short Form-36 (SF-36) physical component score , and the Tegner activity score were used to assess outcomes preoperatively and at 6 months, 1 year, and 2 years postoperatively. The KOOS outcomes at 2 years were compared with historical outcomes following microfracture treatment. Results:. We found significant and clinically meaningful improvements in the KOOS scores, VAS pain score, and SF-36 physical component score (p 40 years). When compared with historical microfracture data, the BioPoly RS Implant demonstrated significantly superior KOOS scores for quality of life and sports. Conclusions:. The present study indicated that the BioPoly RS Partial Resurfacing Knee Implant is safe, that it resulted in significantly improved knee function by 6 months, and that this improvement was sustained for 2 years regardless of patient age. The BioPoly RS Knee Implant allows return to a higher level of sporting activity than microfracture. Additional long-term follow-up is needed to determine the long-term effects of the device. Level of Evidence:. Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.